Robert Ainscow Sells 8,438 Shares of ASP Isotopes (NASDAQ:ASPI) Stock

ASP Isotopes Inc. (NASDAQ:ASPI) COO Robert Ainscow sold 8,438 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $7.00, for a total value of $59,066.00. Following the transaction, the chief operating officer owned 2,281,879 shares of the company’s stock, valued at $15,973,153. The trade was a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Robert Ainscow also recently made the following trade(s):

• On Thursday, April 16th, Robert Ainscow sold 22,500 shares of ASP Isotopes stock. The shares were sold at an average price of $5.21, for a total value of $117,225.00.

ASP Isotopes Stock Down 8.6%

Shares of ASPI traded down $0.55 on Wednesday, hitting $5.85. The company’s stock had a trading volume of 3,997,678 shares, compared to its average volume of 6,216,526. The company has a quick ratio of 4.37, a current ratio of 4.39 and a debt-to-equity ratio of 0.69. The firm’s fifty day moving average price is $5.65 and its 200-day moving average price is $5.84. ASP Isotopes Inc. has a fifty-two week low of $3.92 and a fifty-two week high of $14.49. The firm has a market capitalization of $736.52 million, a price-to-earnings ratio of -2.81 and a beta of 3.42.

ASP Isotopes (NASDAQ:ASPI) last issued its quarterly earnings data on Wednesday, May 20th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.06. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.The business had revenue of $8.36 million during the quarter, compared to analyst estimates of $3.68 million.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 price objective on shares of ASP Isotopes in a research report on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $13.00.

Institutional Investors Weigh In On ASP Isotopes

Several institutional investors have recently bought and sold shares of ASPI. Encompass Capital Advisors LLC bought a new stake in ASP Isotopes in the 1st quarter valued at approximately $30,551,000. Alyeska Investment Group L.P. lifted its stake in ASP Isotopes by 73.4% in the 4th quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock valued at $26,191,000 after acquiring an additional 2,072,851 shares in the last quarter. UBS Group AG lifted its stake in ASP Isotopes by 150.3% in the 4th quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock valued at $12,875,000 after acquiring an additional 1,445,165 shares in the last quarter. Marshall Wace LLP lifted its stake in ASP Isotopes by 3,669.1% in the 3rd quarter. Marshall Wace LLP now owns 1,279,121 shares of the company’s stock valued at $12,305,000 after acquiring an additional 1,245,184 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in ASP Isotopes by 37.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock valued at $43,451,000 after acquiring an additional 1,241,024 shares in the last quarter. Institutional investors own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.